Yahoo Web Search

Search results

1. www.biopharmadive.com › news › lilly-acquireLilly to acquire cancer antibody drug startup Emergence

   www.biopharmadive.com › news › lilly-acquire

   • Cached

   Jun 29, 2023 · Dive Brief: Eli Lilly has reached a deal to acquire Emergence Therapeutics, a German biotechnology startup focused on antibody-drug conjugates, or ADCs, the company confirmed to BioPharma Dive on Thursday.

2. www.life-sciences-europe.com › news › eli-lillyHeidelberg Pharma AG. (6/29/23). "Press Release: Heidelberg ...

   www.life-sciences-europe.com › news › eli-lilly

   • Cached

   Heidelberg Pharma AG (FSE: HPHA) announced today that Eli Lilly and Company will purchase the shares in Emergence Therapeutics AG, Duisburg, Germany, (Emergence), including shares from the conversion of the Emergence convertible bonds, that are held by its subsidiary Heidelberg Pharma Research GmbH as part of Eli Lilly and Company’s ...

   • Group: Eli Lilly (Group)
   • Organisation 2: Emergence Therapeutics AG

   • Organisation: Heidelberg Pharma Research GmbH

3. finance.yahoo.com › quote › APDNApplied DNA Sciences, Inc. (APDN) Latest Stock News ...

   finance.yahoo.com › quote › APDN

   Get the latest Applied DNA Sciences, Inc. (APDN) stock news and headlines to help you in your trading and investing decisions.

4. seekingalpha.com › symbol › APDNApplied DNA Sciences, Inc. (APDN) Latest Stock News

   seekingalpha.com › symbol › APDN

   • Cached

   Get the latest news and real-time alerts from Applied DNA Sciences, Inc. (APDN) stock at Seeking Alpha.

5. www.distilnfo.com › lifesciences › 2023/07/03Lilly to Buy European ADC Player Emergence Therapeutics

   www.distilnfo.com › lifesciences › 2023/07/03

   • Cached

   Jul 3, 2023 · Eli Lilly has acquired European startup Emergence Therapeutics, a biotech focused on developing antibody-drug conjugates (ADCs) for cancers with high unmet need. The most advanced candidate in Emergence’s pipeline is ETx-22, an ADC targeting Nectin-4, a protein found on malignant cells.

6. pitchbook.com › profiles › companyEmergence Therapeutics Company Profile 2024: Valuation ...

   pitchbook.com › profiles › company

   • Cached

   Developer of novel immuno-therapeutics designed to treat high-risk cancers. The company's therapeutics use ATAC technology embracing innovative antibody design, linker technology, and the payload amanitin to target Nectin-4 which is an important and validated target for a broad range of cancers, enabling doctors and healthcare organizations to ...

7. People also ask

   Is Eli Lilly acquiring emergence Therapeutics?

   • Eli Lilly has reached a deal to acquire Emergence Therapeutics, a German biotechnology startup focused on antibody-drug conjugates, or ADCs, the company confirmed to BioPharma Dive on Thursday. In a short statement, European cancer drug developer and founding Emergence investor Heidelberg Pharma said Lilly is acquiring all of the startup’s shares.

   Lilly to acquire cancer antibody drug startup Emergence

   www.biopharmadive.com/news/lilly-acquire-emergence-adc-cancer-drugs/654326/

   See all results for this question

   Will Lilly buy emergence?

   • In a short statement, European cancer drug developer and founding Emergence investor Heidelberg Pharma said Lilly is acquiring all of the startup’s shares. Deal terms weren’t disclosed, but Heidelberg will receive $7 million for its stake in the company. Lilly, in an email, declined to provide more details.

   Lilly to acquire cancer antibody drug startup Emergence

   www.biopharmadive.com/news/lilly-acquire-emergence-adc-cancer-drugs/654326/

   See all results for this question

   Who owns emergence Therapeutics & sigilon Therapeutics?

   • The company on Thursday announced plans to acquire cell therapy developer Sigilon Therapeutics for up to $310 million, and previously announced a $2.4 billion deal to buy inflammatory disease drugmaker Dice Therapeutics. In addition to Heidelberg, Emergence is backed by Pontifax Venture Capital, RA Capital Management and OrbiMed.

   Lilly to acquire cancer antibody drug startup Emergence

   www.biopharmadive.com/news/lilly-acquire-emergence-adc-cancer-drugs/654326/

   See all results for this question

   Who backed emergence?

   • In addition to Heidelberg, Emergence is backed by Pontifax Venture Capital, RA Capital Management and OrbiMed. In 2022, the company struck an ADC-focused deal worth up to $360 million with a Dutch biotech called Synaffix .

   Lilly to acquire cancer antibody drug startup Emergence

   www.biopharmadive.com/news/lilly-acquire-emergence-adc-cancer-drugs/654326/

   See all results for this question

   What is emergence etx-22?

   • Lilly, in an email, declined to provide more details. Emergence’s lead candidate, called ETx-22, focuses on a target called Nectin-4, that’s overexpressed in most bladder cancers. The protein is the focus of other experimental drugs in clinical development, as well as Seagen’s marketed medicine Padcev.

   Lilly to acquire cancer antibody drug startup Emergence

   www.biopharmadive.com/news/lilly-acquire-emergence-adc-cancer-drugs/654326/

   See all results for this question

8. www.benzinga.com › news › 24/08/40533244Why Is Diagnostic Tests Provider Applied DNA Sciences Stock ...

   www.benzinga.com › news › 24/08/40533244

   • Cached

   Aug 23, 2024 · Applied DNA Sciences stock surges as it seeks approval to expand its mpox virus test to cover additional clades. The company awaits a decision from NYSDOH following its validation package ...